

# Old Drug, New Tricks? How the BPCIA Could Increase Generic Competition for Insulins

PUBLICATIONS | LESS THAN 1 MIN READ

June 23, 2020

By: Ted Mathias and Rebecca Clegg


BioProcess Online / Biosimilar Development

*BioProcess Online* and *Biosimilar Development* published “Old Drug, New Tricks? How the BPCIA Could Increase Generic Competition for Insulins,” an article written by Axinn partner Ted Mathias and associate Rebecca Clegg.

Click to access the article on [BioProcess Online](#) and [Biosimilar Development](#).

## Related People

---



Ted Mathias



Rebecca L. Clegg

## Related Services

---

Intellectual Property

To subscribe to our publications, [click here](#).

## Featured Insights

- GCR Live: Law Leaders Europe 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- AHLA Annual Meeting 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- SABA North America Annual Conference 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses  
**WEBINAR    ANTITRUST**
- Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025  
**SPONSORSHIP    ANTITRUST**
- NJSBA Annual Meeting and Convention 2025  
**SPEAKING ENGAGEMENT    INTELLECTUAL PROPERTY**
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You  
**WEBINAR    INTELLECTUAL PROPERTY**

- Hartford HealthCare Black and Red Gala 2025  
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025  
SPEAKING ENGAGEMENT ANTITRUST
- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits  
AXINN VIEWPOINTS LITIGATION & TRIALS